hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic.
The Danish drugmaker plans to make human insulin only available in vials, which would